Bin Xian Wei
Directeur/Membre du Conseil chez PALISADE BIO, INC.
Fortune : 2 251 $ au 31/05/2024
Profil
Bin Xian Wei is an Independent Director at Palisade Bio, Inc. and Vice President at Dar Sheng Trade & Technic Development Co. Ltd.
He previously served as an Independent Director at Seneca Biopharma, Inc. and as a Manager-Business Development at Sakai Trading Co., Ltd.
Mr. Wei holds undergraduate and graduate degrees from Tianjin University and a graduate degree from Colorado School of Mines.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
PALISADE BIO, INC.
0,05% | 11/06/2024 | 467 ( 0,05% ) | 2 251 $ | 31/05/2024 |
Postes actifs de Bin Xian Wei
Sociétés | Poste | Début |
---|---|---|
PALISADE BIO, INC. | Directeur/Membre du Conseil | 01/01/2019 |
Dar Sheng Trade & Technic Development Co. Ltd. | Corporate Officer/Principal | 01/01/2015 |
Anciens postes connus de Bin Xian Wei
Sociétés | Poste | Fin |
---|---|---|
SAKAI TRADING CO., LTD. | Corporate Officer/Principal | 01/01/2010 |
PALISADE BIO, INC. | Directeur/Membre du Conseil | - |
Formation de Bin Xian Wei
Tianjin University | Graduate Degree |
Colorado School of Mines | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PALISADE BIO, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Sakai Trading Co., Ltd.
Sakai Trading Co., Ltd. Wholesale DistributorsDistribution Services Sakai Trading Co., Ltd. engages in imports and exports chemical, synthetic resins and electronic materials. It operates through the Domestic and Overseas segments. The Domestic segment manages the domestic operations of the company's products. The Overseas segment handles the overseas operations through its subsidiaries located overseas. The company was founded February 10, 1936 and is headquartered in Osaka, Japan. | Distribution Services |
Seneca Biopharma, Inc.
Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
Dar Sheng Trade & Technic Development Co. Ltd. |